MAYNE PHARMA GROUP LIMITED — M&A Activity 2025

Nov 19, 2025

==> picture [117 x 45] intentionally omitted <==

ASX Announcement

UPDATE ON STATUS OF FIRB APPROVAL AND SECOND COURT HEARING

20 November 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) ( Mayne Pharma ) refers to its proposed acquisition by Cosette Pharmaceuticals, Inc. ( Cosette ) by way of scheme of arrangement ( Scheme ).

Shortly before release of this announcement, Mayne Pharma was notified that the Foreign Investment Review Board ( FIRB ) had unilaterally extended the statutory deadline for FIRB approval to Friday, 21 November 2025.

Mayne Pharma has rescheduled the Court hearing to approve the Scheme ( Second Court Hearing ) to take place at 3:00pm (AEDT) on Sunday, 23 November 2025.

The Scheme remains subject to FIRB approval, Court approval and other conditions as set out in the Scheme Booklet (and as outlined in clause 3.1 of the Scheme Implementation Deed). On the basis that these conditions are satisfied, an updated indicative timetable is set out below. This timetable remains subject to ASX approval.

Event	Expected Date
Second Court Hearing to Approve the Scheme	Sunday, 23 November 2025
	at 3:00pm AEDT
Effective Date	Monday, 24 November 2025
Mayne Pharma shares will be suspended from trading at the
close of trading on ASX on the Effective Date. If the Scheme
proceeds, this will be the last day that Mayne Pharma shares will
trade on ASX
Scheme Record Date	Wednesday, 26 November
For determiningentitlements to the Scheme consideration	2025 at 7:00pm AEDT
Scheme Implementation Date	Thursday, 4 December 2025
All Scheme shareholders will be sent the Scheme consideration
to which theyare entitled on this date

This timetable is indicative only. All dates and times, unless otherwise indicated, refer to the date and time in Australian Eastern Daylight Savings Time. Any changes to the above timetable will be announced to ASX and notified on Mayne Pharma’s website at maynepharma.com.

Mayne Pharma will keep the market informed as appropriate.

- ENDS -

Authorised for release to the ASX by the Board Chair

==> picture [227 x 54] intentionally omitted <==

==> picture [128 x 46] intentionally omitted <==

ASX Announcement

For further information contact:

Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women’s health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Page 2